HomeCompareCMOPF vs DIVO

CMOPF vs DIVO: Dividend Comparison 2026

CMOPF yields 2.29% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DIVO wins by $7.7K in total portfolio value
10 years
CMOPF
CMOPF
● Live price
2.29%
Share price
$105.00
Annual div
$2.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.1K
Annual income
$264.93
Full CMOPF calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — CMOPF vs DIVO

📍 DIVO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMOPFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMOPF + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMOPF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMOPF
Annual income on $10K today (after 15% tax)
$194.28/yr
After 10yr DRIP, annual income (after tax)
$225.19/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, DIVO beats the other by $609.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMOPF + DIVO for your $10,000?

CMOPF: 50%DIVO: 50%
100% DIVO50/50100% CMOPF
Portfolio after 10yr
$26.9K
Annual income
$623.31/yr
Blended yield
2.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CMOPF right now

CMOPF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
9.2
Piotroski
8/9
DIVO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMOPF buys
0
DIVO buys
0
No recent congressional trades found for CMOPF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMOPFDIVO
Forward yield2.29%6.49%
Annual dividend / share$2.40$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$23.1K$30.7K
Annual income after 10y$264.93$981.68
Total dividends collected$2.5K$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CMOPF vs DIVO ($10,000, DRIP)

YearCMOPF PortfolioCMOPF Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$10,929$228.56$11,349$649.42$420.00DIVO
2$11,927$233.45$12,833$688.83$906.00DIVO
3$13,000$238.11$14,459$727.90$1.5KDIVO
4$14,153$242.55$16,238$766.49$2.1KDIVO
5$15,390$246.78$18,179$804.47$2.8KDIVO
6$16,718$250.80$20,293$841.71$3.6KDIVO
7$18,143$254.62$22,591$878.14$4.4KDIVO
8$19,671$258.24$25,087$913.65$5.4KDIVO
9$21,310$261.68$27,791$948.18$6.5KDIVO
10$23,067$264.93$30,718$981.68$7.7KDIVO

CMOPF vs DIVO: Complete Analysis 2026

CMOPFStock

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Full CMOPF Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this CMOPF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMOPF vs SCHDCMOPF vs JEPICMOPF vs OCMOPF vs KOCMOPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.